Phase 2 Evidence and Impact Analysis
I'll score each article independently, applying conservative caps where applicable (reviews, observational designs, abstract-only access, non-human studies).
Article 1 — Guo et al., Magn Reson Imaging (PMID 42674227)
Convolution-transformer model for HCM vs. phenocopies
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 7 | Hybrid convolution-transformer architecture for a clinically meaningful differential (HCM vs. HHD vs. CA) is architecturally novel; multi-center, multi-device scope adds real-world value |
| Clinical Relevance | 7 | HCM differential diagnosis is a genuine bottleneck; AI assistance could reduce costly workup and misdiagnosis delays |
| Population Reach | 6 | HCM affects ~1 in 500; phenocopy differentiation relevant to broad cardiology practice |
| Implementation Speed | 5 | Multi-center validation demonstrated; regulatory pathway and EHR integration remain |
| Evidence Strength | 5 | Cohort/observational, abstract-only; no sample size, performance metrics (AUC, sensitivity/specificity) reported; single-study |
Key quantitative result: Not extractable from abstract — no AUC or accuracy figures reported. External validation: Multi-center, multi-device framing suggests some internal validation diversity, but no independent external cohort confirmed. Main limitation: Abstract-only; no performance metrics visible; unclear training/test split rigor. Equity: Benefits patients at specialist centers with MRI access; may widen gap for low-resource settings without MRI infrastructure. Evidence Maturity (revised): Exploratory (downgraded from Validated — no metrics available; single study)
Article 2 — He et al., BMJ Open Diabetes Res Care (PMID 42674805)
Stress hyperglycemia ratio (SHR) prognostic meta-analysis in PCI patients
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 5 | SHR concept well-established; this adds dose-response modelling — incremental rather than transformative |
| Clinical Relevance | 8 | PCI is one of the most common procedures in cardiology; a readily calculable ratio that predicts outcomes could directly guide peri-procedural management |
| Population Reach | 8 | Hundreds of thousands of PCI procedures performed annually worldwide; diabetic and non-diabetic patients both affected |
| Implementation Speed | 7 | SHR requires only routine labs (glucose + HbA1c); no new tools needed; guideline incorporation is the primary barrier |
| Evidence Strength | 6 | Meta-analysis is strongest available design, but explicitly observational source studies; dose-response curve adds rigor; publication bias risk noted |
Key quantitative result: Not extractable from abstract — dose-response relationship reported but thresholds not quoted. External validation: Pooled multi-study meta-analysis provides implicit cross-study replication. Main limitation: Observational source data only; residual confounding; limited studies for some sub-analyses; no RCT validation of SHR-guided management. Equity: Benefits all PCI populations including under-monitored diabetics; implementation is low-cost and does not require new technology — favorable equity profile. Evidence Maturity (confirmed): Potentially Practice-Changing (conditional on RCT confirmation of SHR-guided protocols)
Article 3 — Yao et al., J Formos Med Assoc (PMID 42674925)
Clonal hematopoiesis and atherosclerotic cardiovascular disease: review
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 7 | CH as a cardiovascular risk mediator is a rapidly evolving paradigm; the inflammation-driven precision cardiology framing is genuinely new to mainstream practice |
| Clinical Relevance | 6 | Mechanistic insights are strong, but no therapeutic intervention validated yet; review does not provide actionable protocol changes today |
| Population Reach | 8 | CH prevalence rises sharply with age (>10% over age 70); ASCVD is the leading cause of death globally — intersection affects tens of millions |
| Implementation Speed | 2 | Currently exploratory; no CH-targeted therapies approved; testing not routine; 10+ year horizon for clinical implementation |
| Evidence Strength | 3 | Narrative review; mixed species evidence; no original data; evidence quality of underlying studies varies widely |
Key quantitative result: None provided. External validation: Review synthesizes existing literature; no new data generated. Main limitation: Review design cannot establish causation; therapeutic strategies described are all investigational; mixed human/animal data. Equity: If CH screening becomes routine, access will initially favor wealthy health systems with genomic testing infrastructure. Low-income populations with higher CVD burden may benefit most but access last. Evidence Maturity (revised): Exploratory (confirmed; the review maps a field but does not validate a clinical action)
Article 4 — Raihane et al., Acad Radiol (PMID 42674935)
Sixty years of lung cancer screening: narrative review
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 3 | Comprehensive synthesis, but narrative reviews of LDCT screening history add limited new knowledge |
| Clinical Relevance | 6 | Useful for clinicians and policymakers implementing screening programs; Lung-RADS evolution is clinically meaningful |
| Population Reach | 8 | Lung cancer is the leading cause of cancer death; screening eligibility has been expanded in recent guidelines |
| Implementation Speed | 5 | LDCT screening is already guideline-endorsed; emerging technologies (AI, liquid biopsy) discussed are not yet standard |
| Evidence Strength | 3 | Narrative review; no systematic methods or primary data |
Key quantitative result: Lung-RADS described as substantially reducing false-positive rates (no specific figures in abstract). External validation: N/A (review). Main limitation: Narrative (not systematic) synthesis; may be selective; no new data. Equity: Screening historically underused in Black patients, low-income groups, and women — equity gaps noted in literature though not prominently featured in this abstract. Evidence Maturity (revised): Exploratory (confirmed; educational synthesis, not a primary evidence contribution)
Article 5 — Khan & Cho, Anticancer Res (PMID 42674700)
Transcriptomic profiling of adhesion GPCRs in pancreatic adenocarcinoma
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 7 | Systematic characterization of aGPCR dysregulation in PAAD using TCGA is relatively unexplored; ADGRG7 and ADGRF1 as novel targets is genuinely novel |
| Clinical Relevance | 3 | Pure discovery/bioinformatics; no therapeutic or diagnostic application demonstrated |
| Population Reach | 6 | Pancreatic cancer has dismal prognosis (~11% 5-yr survival) and large unmet need; any target discovery has high potential value |
| Implementation Speed | 1 | Preclinical bioinformatics; 10+ years from clinical application |
| Evidence Strength | 3 | Unspecified study design; TCGA-only; abstract truncated; no functional validation described |
Key quantitative result: "Massive upregulation" of aGPCRs described but no fold-change or p-values extractable. External validation: None described. Main limitation: Computational only; no wet-lab validation; TCGA data limitations; sample size not reported. Equity: Discovery phase — equity implications premature to assess. Evidence Maturity (revised): Exploratory (confirmed)
Article 6 — Tahir et al., PLoS One (PMID 42671999)
Safety of neoadjuvant RT/CRT + immunotherapy: systematic review protocol
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 3 | Protocol paper only — no results yet; the question itself is clinically important but well-recognized |
| Clinical Relevance | 5 | Safety data will be practice-relevant when complete; protocol alone cannot change practice |
| Population Reach | 7 | Resectable solid tumors represent a large patient population across multiple cancer types |
| Implementation Speed | 3 | Protocol not yet executed; results 1–3 years away minimum |
| Evidence Strength | 3 | Protocol paper; no results; "RCT (inferred)" study design label is misleading — this is a planned systematic review |
Key quantitative result: None — protocol only. External validation: N/A. Main limitation: No data yet available; study design classification as RCT appears to be a Phase 1 pipeline error (this is a systematic review protocol). Equity: Safety signal identification could particularly benefit patients at centers with limited monitoring capacity. Evidence Maturity (revised): Exploratory (downgraded from Potentially Practice-Changing — protocol only)
Article 7 — Wang et al., J Clin Lipidol (PMID 42674889)
Olezarsen efficacy/safety with vs. without baseline fibrate
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | Olezarsen (APOC3 ASO) is a novel drug class; fibrate interaction analysis adds clinically useful subgroup data |
| Clinical Relevance | 8 | Hypertriglyceridemia with pancreatitis risk is a real unmet need; complementary mechanisms with fibrates is directly actionable if confirmed |
| Population Reach | 7 | Millions with severe hypertriglyceridemia; high-risk subgroups (familial chylomicronemia syndrome) especially affected |
| Implementation Speed | 5 | Phase 3 data published; regulatory approval pathway likely underway; formulary access is the primary barrier |
| Evidence Strength | 7 | Phase 3 trial (inferred from "phase 3 trials" mentioned in abstract); RCT-level evidence; multi-country investigators |
Key quantitative result: Complementary triglyceride-reducing mechanisms suggested; no specific TG reduction percentages extractable from abstract. External validation: Phase 3 trial provides high-quality evidence; subgroup analysis is secondary/exploratory. Main limitation: Subgroup analysis (fibrate use) is post-hoc and hypothesis-generating; limited sample in fibrate subgroup. Equity: Novel ASO therapies are typically high-cost; access barriers significant in low/middle-income countries and uninsured patients. Evidence Maturity (confirmed): Potentially Practice-Changing
Article 8 — Friuli et al., Br J Pharmacol (PMID 42674554)
Oleoylethanolamide (OEA) in obesity and comorbidities: review
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | OEA as a multi-target metabolic modulator positioned alongside GLP-1 agonists is a fresh conceptual angle |
| Clinical Relevance | 4 | No clinical OEA trials with meaningful outcomes yet; primarily mechanistic positioning |
| Population Reach | 9 | Global obesity epidemic; potential relevance to billions |
| Implementation Speed | 1 | Preclinical/early clinical; 10+ years from clinical use |
| Evidence Strength | 3 | Narrative review; mixed species evidence; no original data |
Key quantitative result: None. External validation: N/A. Main limitation: Review of largely preclinical data; clinical translation entirely unproven. Equity: If developed as an affordable oral agent, could be more equitably accessible than injectable biologics. Evidence Maturity (revised): Exploratory (confirmed)
Article 9 — Valenzuela-Fuenzalida et al., Clin Nutr ESPEN (PMID 42674359)
Mediterranean diet in NAFLD/MASLD: systematic review and meta-analysis of RCTs
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 4 | Mediterranean diet in NAFLD is well-studied; meta-analysis consolidates but does not fundamentally change the field |
| Clinical Relevance | 7 | MASLD affects ~25% of the global population; dietary guidance directly actionable in clinical and primary care settings |
| Population Reach | 9 | MASLD is the most common chronic liver disease worldwide |
| Implementation Speed | 8 | Dietary intervention — no regulatory or cost barriers; immediately implementable with clinical guidance |
| Evidence Strength | 6 | RCT-based meta-analysis is a strength; high heterogeneity (I² moderate-high) substantially limits interpretation |
Key quantitative result: High heterogeneity across outcomes — specific effect sizes not extractable from abstract. External validation: Meta-analysis of multiple RCTs provides cross-study replication, but heterogeneity undermines pooled estimates. Main limitation: High heterogeneity; likely variable diet adherence measurement; short trial durations common in dietary RCTs. Equity: Mediterranean diet requires access to diverse fresh foods and may be culturally inappropriate or cost-prohibitive for some populations. Evidence Maturity (confirmed): Potentially Practice-Changing (with caveats about heterogeneity)
Article 10 — Cheung, Drug Des Devel Ther (PMID 42670437)
Translational framework for glutamatergic/senescence-modulating strategies in TRD
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 5 | Linking senescence biology to TRD treatment development is conceptually interesting but speculative |
| Clinical Relevance | 5 | TRD has enormous unmet need; framework is theoretical, not prescriptive |
| Population Reach | 7 | TRD affects ~30% of depression patients; depression affects ~280 million globally |
| Implementation Speed | 2 | Purely theoretical framework; no clinical data; requires full drug development pipeline |
| Evidence Strength | 2 | Single-author opinion/framework paper; explicitly not a systematic review; no original data |
Key quantitative result: None. External validation: N/A. Main limitation: No original data; high speculation; study design classification as "Meta-Analysis/Systematic Review (inferred)" is an error — this is a narrative opinion framework. Equity: TRD disproportionately affects individuals with limited access to specialty psychiatric care; novel oral agents could democratize treatment if developed. Evidence Maturity (revised): Exploratory (downgraded from Potentially Practice-Changing — theoretical framework only)
Article 11 — Sturley et al., Heart (PMID 42674969)
Geographic variation in long-term outcomes following MI in England
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 5 | Geographic health inequity after MI is well-documented; this adds granular commissioning-area data for England |
| Clinical Relevance | 7 | Findings directly inform resource allocation and intervention targeting for commissioners |
| Population Reach | 8 | MI is one of the most common acute cardiac events; geographic disparities affect hundreds of thousands in England alone |
| Implementation Speed | 6 | Policy-level implementation; commissioning decisions can be made relatively quickly if data is compelling |
| Evidence Strength | 6 | Cohort study using national data — strong ecological design; note the "RCT (inferred)" classification is incorrect |
Key quantitative result: Geographic variation in health outcomes post-MI quantified but specific figures not extractable. External validation: National database — high coverage; no external cohort validation needed for descriptive study. Main limitation: Ecological study; cannot attribute variation to specific healthcare system factors vs. patient population differences; limited to England. Equity: Core equity study — directly maps health disparities; findings actionable for reducing inequity. Evidence Maturity (revised): Validated (downgraded from Potentially Practice-Changing — descriptive study; no intervention tested)
Article 12 — Michelis et al., Curr Opin Hematol (PMID 42673525)
Proteomics for biomarker discovery in allo-HCT complications
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 5 | Proteomics in transplant complications is an active but not fully mature area; review summarizes the landscape |
| Clinical Relevance | 7 | Delayed diagnosis of GVHD, VOD, and TMA carries high mortality; early protein biomarkers could transform post-transplant management |
| Population Reach | 4 | Allo-HCT is performed in ~50,000 patients/year globally — smaller population, but unmet need is critical |
| Implementation Speed | 4 | Requires multicenter validation, biobanking harmonization, and clinical integration — several years away |
| Evidence Strength | 4 | Review of proteomic discovery studies; most underlying data is exploratory; explicit statement that validation not yet complete |
Key quantitative result: None. External validation: Explicitly notes multicenter validation is required. Main limitation: Discovery-stage biomarkers; no validated clinical assay yet; pre-analytical variability in proteomics. Equity: Transplant recipients are already a privileged subset of hematology patients; access to advanced proteomic monitoring will further concentrate in academic centers. Evidence Maturity (confirmed): Validated (in the sense that proteomic approaches are well-characterized; not yet clinically implemented)
Article 13 — Zhang et al., Blood Cancer Discov (PMID 42671911)
Phosphorylation protects oncogenic RAS from LZTR1-mediated degradation in blood cancers
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 8 | Identification of a phosphorylation-dependent protection circuit that specifically stabilizes oncogenic RAS in hematologic malignancies is genuinely novel and mechanistically important |
| Clinical Relevance | 4 | Preclinical discovery; "potentially druggable" but no drug candidate or clinical data |
| Population Reach | 6 | RAS mutations are common in multiple myeloma and other blood cancers — substantial potential population |
| Implementation Speed | 2 | Basic science discovery; 10+ years from clinical application |
| Evidence Strength | 5 | Multi-omics approach in human cell lines and patient samples; rigorous methodology implied but no clinical data; abstract-only |
Key quantitative result: Not extractable. External validation: Not described in abstract. Main limitation: Preclinical; no in vivo models described; druggability of the phosphorylation site unproven. Equity: N/A at this stage. Evidence Maturity (confirmed): Exploratory
Article 14 — Bhatt et al., Am J Hematol (PMID 42671879)
Primary plasma cell leukemia: review
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 5 | Comprehensive current review of a rare entity; some novelty in framing emerging therapies |
| Clinical Relevance | 6 | PCL has dismal outcomes and no standard of care; review from leading myeloma centers (Mayo Clinic) carries authority |
| Population Reach | 3 | PCL = 1–2% of myeloma diagnoses; extremely rare |
| Implementation Speed | 4 | Review synthesizes existing therapeutic options; emerging therapies (CAR-T, bispecifics) may be more rapidly accessible than indicated |
| Evidence Strength | 3 | Narrative review; no primary data |
Key quantitative result: None. External validation: N/A. Main limitation: Extremely limited trial data for PCL specifically; most evidence extrapolated from myeloma trials. Equity: Rare disease — patients at non-specialist centers are particularly disadvantaged; trial access is geographically restricted. Evidence Maturity (confirmed): Exploratory
Article 15 — Dervis et al., Lung Cancer (PMID 42673682)
AI for thoracic lymphadenopathy identification in lung cancer
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 5 | AI-based lymph node detection on CT is an active but crowded field; the comparison with routine radiology reporting and histopathology is a useful contribution |
| Clinical Relevance | 7 | Missed lymph nodes in lung cancer staging directly affects surgical decisions and survival; AI support for systematic reporting is clinically meaningful |
| Population Reach | 7 | Lung cancer is the most common cause of cancer death; accurate staging affects all surgical candidates |
| Implementation Speed | 5 | Multi-center IRB-approved study; 169 patients — limited scale; regulatory clearance pathway is the main barrier |
| Evidence Strength | 5 | Multicenter, IRB-approved, with histopathologic ground truth — better than average for AI imaging studies, but small n and abstract-only |
Key quantitative result: AI identified more pathologically sampled lymph node stations than documented in routine reports. External validation: Multicenter design provides some generalizability. Main limitation: N=169; single time-window CT-to-sampling; abstract-only; no sensitivity/specificity figures. Equity: Could improve staging in centers without dedicated thoracic radiologists. Evidence Maturity (revised): Exploratory (downgraded from flagged as near-term — sample size too small)
Article 16 — Khan, Radiol Technol (PMID 42671965)
AI-assisted sonography for thyroid nodule diagnosis: systematic review
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 4 | AI for thyroid nodule classification is well-trodden; systematic review consolidates but doesn't advance the field materially |
| Clinical Relevance | 7 | Unnecessary thyroid biopsies are a major quality problem; reducing them with AI is immediately actionable |
| Population Reach | 7 | Thyroid nodules are extremely common (~65% prevalence on ultrasound in adults) |
| Implementation Speed | 6 | AI thyroid US tools exist commercially; integration into workflow is the primary barrier |
| Evidence Strength | 5 | Systematic review methodology (2018–2025 literature); abstract-only; unable to assess pooled metrics or heterogeneity |
Key quantitative result: Not extractable. External validation: Systematic review pools multiple studies. Main limitation: Abstract-only; quality of included studies unclear; mixed species note in pipeline is likely erroneous for this human-focused review. Equity: AI assistance could particularly benefit lower-volume centers and non-specialist ultrasonographers. Evidence Maturity (confirmed): Potentially Practice-Changing (AI thyroid US is approaching routine use in some settings)
Article 17 — Carta et al., Eur Urol Oncol (PMID 42674932)
Actionable genetic alterations in advanced urothelial carcinoma
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 5 | Real-world MTB-guided actionability gap is a recognized problem; this adds European real-world data |
| Clinical Relevance | 7 | FGFR3 testing and erdafitinib eligibility determination is directly actionable today; MTB adherence gap is clinically urgent |
| Population Reach | 6 | Bladder cancer is the 6th most common cancer; mUC has high unmet need post-platinum |
| Implementation Speed | 6 | FDA/EMA-approved drug exists; gap is physician adherence and tumor board access, not technology |
| Evidence Strength | 5 | Real-world cohort; MTB-based approach with evidence-based recommendations; abstract-only; no sample size visible |
Key quantitative result: High prevalence of actionable findings observed; significant gap between detection and treatment use — no specific percentages extractable. External validation: Single center; requires multi-center replication. Main limitation: Single-center; retrospective; abstract-only; selection bias possible. Equity: MTB access is geographically and institutionally unequal; finding highlights systemic access problem. Evidence Maturity (confirmed): Validated (demonstrates a real-world gap; does not validate a new intervention)
Article 18 — Shao et al., Cancer Genomics Proteomics (PMID 42674822)
ERP44 as prognostic biomarker and TMZ resistance factor in lower-grade glioma
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | ERP44 as a TMZ resistance driver in LGG is a novel finding with therapeutic implications |
| Clinical Relevance | 4 | Preclinical/bioinformatics finding; no clinical validation; TMZ is already standard of care |
| Population Reach | 4 | LGG is a relatively rare brain tumor; affects younger adults disproportionately |
| Implementation Speed | 3 | Discovery-stage; validation required before clinical use |
| Evidence Strength | 4 | Cohort + knockdown experiments; TCGA-based; abstract-only |
Key quantitative result: ERP44 knockdown reduced proliferation and colony formation, reduced TMZ IC₅₀ — specific numbers not available. External validation: Not described. Main limitation: Bioinformatics + cell line study; no patient treatment validation. Equity: Brain cancer patients in low-resource settings have limited access to molecular profiling. Evidence Maturity (confirmed): Validated (biomarker association validated in silico/in vitro; not clinically validated)
Article 19 — Zeng et al., Cancer Genomics Proteomics (PMID 42674818)
Multi-omics of CRC immune microenvironment
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 5 | Multi-omics immune characterization of CRC is well-studied; CD4+ T cell infiltration as regulatory focus is incremental |
| Clinical Relevance | 4 | Identifies candidate targets; no clinical validation; immunotherapy for CRC is already an active field |
| Population Reach | 8 | CRC is the 3rd most common cancer and 2nd cause of cancer death globally |
| Implementation Speed | 2 | Discovery-stage; 10+ years from clinical use |
| Evidence Strength | 4 | Cohort of 1,539 IRG analysis; TCGA-based; abstract-only; no clinical outcome data |
Key quantitative result: 1,539 immune-related genes analyzed; CD4+ infiltration associations identified — no specific effect sizes. External validation: None described. Main limitation: Computational only; no wet-lab or clinical validation. Equity: N/A at discovery stage. Evidence Maturity (revised): Exploratory (downgraded from Validated — no clinical validation present)
Article 20 — Cabanillas et al., Eur J Cancer (PMID 42673705)
Lenvatinib + pembrolizumab in non-BRAF-mutated anaplastic thyroid cancer: phase 2
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 7 | First prospective phase 2 data for lenvatinib + pembrolizumab in BRAF wild-type ATC — fills a critical therapeutic gap for ~60% of ATC patients |
| Clinical Relevance | 9 | ATC has median survival of 3–5 months; this combination shows clinically meaningful OS in a population with no approved options — potentially practice-defining |
| Population Reach | 3 | ATC is very rare (~1–2% of thyroid cancers); but unmet need is extreme |
| Implementation Speed | 6 | Phase 2 data; both drugs are approved for other indications; off-label use or expanded access feasible; phase 3 or FDA submission likely next |
| Evidence Strength | 7 | Phase 2 clinical trial; NCT registered; single-center at MD Anderson limits generalizability; abstract-only prevents full assessment |
Key quantitative result: "Clinically meaningful OS" in BRAF wild-type ATC — specific median OS not extractable from abstract. External validation: Single-center phase 2; requires multicenter confirmation. Main limitation: Single-center; small likely n (ATC trials are typically n<50); non-randomized; abstract-only. Equity: ATC disproportionately affects elderly patients; access to specialty thyroid oncology centers is geographically unequal. Evidence Maturity (confirmed): Validated (phase 2 human trial data in a real unmet-need population)
Articles 21–70 (Abbreviated Scoring — Standard Priority)
For efficiency, articles with triage scores ≤7 that are below the top analytical tier are summarized with key dimensions:
| # | PMID | Article (Short) | Novelty | Clin Rel | Pop Reach | Impl Speed | Evid Strength | Composite* | Flag |
|---|---|---|---|---|---|---|---|---|---|
| 21 | 42674899 | DM complications in HIV | 5 | 7 | 6 | 4 | 3 | 5.6 | ⚪ |
| 22 | 42674726 | SGLT2i antiproteinuric effect in HCC+Ate/Bev | 5 | 6 | 5 | 5 | 4 | 5.3 | ⚪ |
| 23 | 42671457 | Inflammaging and MI in aging | 5 | 5 | 7 | 2 | 3 | 4.8 | ⚪ |
| 24 | 42671002 | Robotic surgery in Australasian gynecology | 3 | 4 | 4 | 4 | 3 | 3.7 | ⚪ |
| 25 | 42674209 | Rare disease investment benchmarks | 4 | 5 | 6 | 3 | 3 | 4.6 | 🟡 |
| 26 | 42671976 | Transplant-eligible DLBCL proportion (German billing) | 3 | 5 | 5 | 4 | 3 | 4.3 | 🟢 |
| 27 | 42671910 | CD19 expression and CAR-T outcomes in LBCL | 6 | 8 | 5 | 6 | 6 | 6.5 | 🟢 |
| 28 | 42671909 | PD-1 expression: peripheral vs. bone marrow in DLBCL | 4 | 5 | 5 | 4 | 4 | 4.6 | ⚪ |
| 29 | 42671525 | Aβ antimicrobial peptides | 5 | 2 | 3 | 2 | 3 | 3.0 | ⚪ |
| 30 | 42674905 | Digital monitoring in MS (wearables) | 4 | 6 | 6 | 4 | 3 | 5.0 | 🟢 |
| 31 | 42674877 | Metastatic anal canal cancer: therapeutics review | 4 | 5 | 4 | 3 | 3 | 4.1 | 🔴 |
| 32 | 42674718 | Breast MRI abbreviated protocol for microcalcifications | 4 | 6 | 6 | 5 | 4 | 5.3 | 🔴 |
| 33 | 42674350 | Scotland Detect Cancer Early: process evaluation | 3 | 4 | 6 | 4 | 3 | 4.1 | ⚪ |
| 34 | 42674310 | cfDNA fragmentomics + protein biomarkers for gastric cancer | 6 | 5 | 7 | 3 | 4 | 5.2 | 🔴 |
| 35 | 42673809 | ICU nurses knowledge on pressure ulcer prevention | 2 | 3 | 5 | 5 | 3 | 3.5 | ⚪ |
| 36 | 42673681 | AI for graft rejection prediction: systematic review | 5 | 6 | 5 | 4 | 4 | 5.1 | 🟢 |
| 37 | 42674709 | AI + logistic regression for acute appendicitis | 5 | 6 | 8 | 5 | 4 | 5.9 | ⚪ |
| 38 | 42674284 | Deep learning cardiac MRI in pediatric CHD | 6 | 7 | 5 | 6 | 5 | 6.1 | ⚪ |
| 39 | 42674130 | LLMs vs. NASS CPT coding | 4 | 5 | 6 | 5 | 4 | 4.9 | 🟢 |
| 40 | 42673901 | Deep learning for ovarian torsion prediction | 5 | 6 | 5 | 4 | 4 | 5.1 | ⚪ |
| 41 | 42673789 | ML vs. logistic regression for Kawasaki disease | 4 | 6 | 4 | 3 | 4 | 4.6 | ⚪ |
| 42 | 42673706 | Placental transcriptomics in GDM | 4 | 5 | 6 | 4 | 4 | 4.8 | 🟢 |
| 43 | 42673581 | AI-triaged worklists: radiology turnaround times | 5 | 7 | 8 | 7 | 5 | 6.4 | ⚪ |
| 44 | 42674823 | MI-POG: mutual information biomarker discovery | 3 | 4 | 6 | 3 | 3 | 4.0 | ⚪ |
| 45 | 42674820 | MZT1 as prognostic marker in lung adenocarcinoma | 4 | 4 | 6 | 2 | 3 | 4.0 | ⚪ |
| 46 | 42674724 | KK-LC-1 in lung adenocarcinoma: IHC + TCR therapy target | 5 | 5 | 6 | 3 | 3 | 4.6 | ⚪ |
| 47 | 42674711 | MMP-2 polymorphism in HCC (Taiwanese males) | 3 | 4 | 5 | 3 | 3 | 3.7 | ⚪ |
| 48 | 42674689 | LMR dynamics + AFP in advanced HCC/Ate+Bev | 5 | 6 | 5 | 5 | 4 | 5.3 | ⚪ |
| 49 | 42674680 | Stromal patterns in dedifferentiated liposarcoma | 4 | 4 | 3 | 3 | 4 | 3.7 | ⚪ |
| 50 | 42674319 | Peptide-drug conjugates for cancer therapy: review | 5 | 4 | 6 | 3 | 3 | 4.4 | ⚪ |
| 51 | 42674706 | Response patterns to durvalumab/tremelimumab vs. ate/bev in HCC | 4 | 6 | 5 | 5 | 4 | 5.0 | ⚪ |
| 52 | 42673464 | mRNA vaccine + ICI survival differences: Medicare analysis | 6 | 7 | 9 | 5 | 6 | 6.8 | ⚪ |
| 53 | 42675010 | CVD prevention barriers in HIV patients (Southern US) | 4 | 6 | 6 | 5 | 4 | 5.3 | 🟡 |
| 54 | 42674302 | Lithium and vascular calcification in bipolar disorder | 5 | 6 | 5 | 5 | 4 | 5.3 | 🟢 |
| 55 | 42670341 | Upper tract urothelial carcinoma regional quality differences | 4 | 5 | 4 | 5 | 4 | 4.6 | 🟡 |
| 56 | 42675007 | CRC timeliness and travel distance in Veterans | 4 | 6 | 6 | 5 | 4 | 5.3 | ⚪ |
| 57 | 42674857 | Cancer cachexia prevalence and impact on death | 4 | 6 | 7 | 5 | 4 | 5.5 | ⚪ |
| 58 | 42674787 | ML comorbidity clusters in Pakistani diabetes patients | 5 | 6 | 7 | 4 | 5 | 5.7 | 🟡 |
| 59 | 42674924 | Prediction scores for IVLBCL random skin biopsy: external validation | 5 | 6 | 3 | 5 | 5 | 5.1 | ⚪ |
| 60 | 42674230 | Diffusion MRI CNS microstructural changes in DLBCL | 6 | 5 | 4 | 3 | 4 | 4.6 | ⚪ |
| 61 | 42673946 | Non-genetic remodeling drives AML propagation | 7 | 4 | 5 | 2 | 4 | 4.7 | ⚪ |
| 62 | 42671627 | RL parameterization for anisotropic cellulose (non-clinical) | 3 | 1 | 1 | 1 | 2 | 1.7 | ⚪ |
| 63 | 42674880 | Graph neural network for breast US malignancy detection | 5 | 5 | 7 | 3 | 3 | 4.9 | ⚪ |
| 64 | 42674666 | Autofluorescence imaging for actinic cheilitis | 4 | 4 | 3 | 3 | 3 | 3.6 | ⚪ |
| 65 | 42674031 | LAMP+PfAgo for EGFR mutation detection in ctDNA | 6 | 4 | 6 | 2 | 3 | 4.4 | 🔴 |
| 66 | 42673996 | Lynch syndrome colonoscopy quality benchmarking (UK NED) | 5 | 6 | 5 | 5 | 4 | 5.3 | 🔴 |
| 67 | 42673659 | TiO₂/BiOI photoelectrochemical biosensor for urinary cancer markers | 4 | 3 | 5 | 2 | 3 | 3.5 | 🔴 |
| 68 | 42674933 | LLMs on FRCR Part 1 radiology exam | 4 | 3 | 4 | 4 | 3 | 3.6 | ⚪ |
| 69 | 42674224 | DL reconstruction of low-field brain MRI | 4 | 5 | 6 | 4 | 3 | 4.7 | ⚪ |
| 70 | 42674155 | DL for oral SCC in oral submucous fibrosis (WSI) | 4 | 3 | 4 | 3 | 3 | 3.5 | ⚪ |
(Composite = weighted: ClinRel 30% + PopReach 25% + Novelty 20% + ImplSpeed 15% + EvStrength 10%)
Remaining articles 71–100 (triage score ≤5, mostly abstract-only, preclinical, case reports, or editorials) are not scored individually as they fall below the minimum threshold for ranking consideration.